粪菌移植治疗肠易激综合征患者的临床疗效观察

Fecal microbiota transplantation for patients with irritable bowel syndrome

目的分析粪菌移植(FMT)治疗肠易激综合征(IBS)患者的临床疗效。方法选取2017年3月至2019年2月广州市第一人民医院与海南省中医院收治的共102例IBS患者为研究对象,采用信封分配隐藏方案将患者分为观察组与对照组,每组各51例。对照组予以益生菌制剂口服及常规生活饮食调理,观察组在此基础上予以FMT,比较两组治疗有效率、IBS生活质量专用量表评分(IBS-QOL),记录治疗不良反应。结果观察组治疗总有效率为88.2%(45/51),对照组为62.7%(32/51),两组比较差异有统计学意义(P<0.05)。治疗前,两组IBS-QOL评分比较差异无统计学意义(P>0.05)。治疗后,两组IBS-QOL评分低于组内治疗前,观察组IBS-QOL评分低于对照组(均P<0.05)。两组治疗不良反应发生率比较差异无统计学意义(P>0.05)。结论对接受益生菌制剂口服及常规生活饮食调理的IBS患者加以FMT治疗可取得更好的疗效,还可提高其生活质量,安全性良好。

Objectives To investigate the effect of fecal microbiota transplantation on treating patients with irritable bowel syndrome(IBS).Methods One hundred and two patients with IBS treated at the First People’s Hospital of Guangzhou and the Hainan Hospital of Traditional Chinese Medicine between March 2017 and February 2019 were recruited.Patients were assigned to the treatment and control groups using sealed envelopes with 51 patients in each group.Patients in the control group received oral probiotics and instructions on life-style and diets,and patients in the treatment group received fecal microbiota transplantation in addition to the invention of the control group.Efficacy and scores of Irritable Bowel Syndrome Quality of Life(IBS-QOL)questionnaire were compared between the two groups.Side effects were recorded.Results Overall effectiveness rate was 88.2%(45 out of 51 patients)in the treatment group and 62.7%(32 out of 51 patients)in the control group with a significant betweengroup difference(P<0.05).The score of IBS-QOL before intervention did not differ significantly between the two groups(P>0.05).After the intervention,IBS-QOL decreased in both groups with a significantly lower score in the treatment group(P<0.05).The incidence of side effects was similar between the two groups(P>0.05).Conclusion In patients with IBS,based on oral probiotics and instructions on life-style and diets,fecal microbiota transplantation was effective.It was safe and could improve patients’quality of life.